Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Frequently asked questions
What sector does Palisade Bio Inc (PALI) operate in?
Palisade Bio Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Palisade Bio Inc (PALI) current stock price?
As of the latest data, Palisade Bio Inc stock price is $2.04, with a previous close of $2.15. Palisade Bio Inc lost -$0.11 in the last trading session, representing a -5.12% loss.
What is Palisade Bio Inc (PALI) current market capitalization?
Palisade Bio Inc market cap is approximately 355.51 million.
What is Palisade Bio Inc (PALI) Earnings Per Share (EPS)?
The trailing EPS is $0.65, and the forward EPS is -$0.28.
What is Palisade Bio Inc (PALI) Price-to-Earnings (P/E) ratio?
Palisade Bio Inc current P/E ratio is 3.14.
What is Palisade Bio Inc (PALI) EBITDA?
Palisade Bio Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -10.57 million.
Does Palisade Bio Inc (PALI) pay dividends?
No. Palisade Bio Inc does not pay a dividend.
What is Palisade Bio Inc (PALI) beta (volatility) score?
Palisade Bio Inc has a beta of 1.538, suggesting it is more volatile than the market.
